Clinical trial NCT01369056 - References

Medication Adherence — HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence

Citation(s)

•   Abel-Ollo K, Rahu M, Rajaleid K, Talu A, Ruutel K, Platt L, Bobrova N, Rhodes T, Uuskula A
  Knowledge of HIV serostatus and risk behaviour among injecting drug users in Estonia. AIDS Care. 2009 Jul;21(7):851-7. doi: 10.1080/09540120802657522.
•   Altice FL, Springer S, Buitrago M, Hunt DP, Friedland GH
  Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health. 2003 Sep;80(3):416-27.
•   Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D, Eckholdt H, Howard AA, Schoenbaum EE
  Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001 Oct 15;33(8):1417-23. Epub 2001 Sep 5.
•   Celentano DD, Vlahov D, Cohn S, Shadle VM, Obasanjo O, Moore RD
  Self-reported antiretroviral therapy in injection drug users. JAMA. 1998 Aug 12;280(6):544-6.
•   Charnaz, K
  Constructing Grounded Theory. A Practical Guide Through Qualitative Analysis. London, Sage Publication, 2006.
•   Chesney M
  Adherence to HAART regimens. AIDS Patient Care STDS. 2003 Apr;17(4):169-77. Review.
•   Choo PW, Rand CS, Inui TS, Lee ML, Cain E, Cordeiro-Breault M, Canning C, Platt R
  Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care. 1999 Sep;37(9):846-57.
•   Clayson DJ, Wild DJ, Quarterman P, Duprat-Lomon I, Kubin M, Coons SJ
  A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics. 2006;24(8):751-65. Review.
•   Gross R, Yip B, Lo Re V 3rd, Wood E, Alexander CS, Harrigan PR, Bangsberg DR, Montaner JS, Hogg RS
  A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis. 2006 Oct 15;194(8):1108-14. Epub 2006 Sep 12.
•   Grossberg R, Zhang Y, Gross R
  A time-to-prescription-refill measure of antiretroviral adherence predicted changes in viral load in HIV. J Clin Epidemiol. 2004 Oct;57(10):1107-10.
•   Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J
  Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with non-adherence to HAART. Int J STD AIDS. 2004 Jan;15(1):38-44.
•   Horne R, Cooper V, Gellaitry G, Date HL, Fisher M
  Patients' perceptions of highly active antiretroviral therapy in relation to treatment uptake and adherence: the utility of the necessity-concerns framework. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):334-41.
•   Krüsi A, Wood E, Montaner J, Kerr T
  Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy. 2010 Jan;21(1):4-9. doi: 10.1016/j.drugpo.2009.08.003. Epub 2009 Sep 10.
•   Lerner BH, Gulick RM, Dubler NN
  Rethinking nonadherence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med. 1998 Oct 1;129(7):573-8. Review.
•   Lucas GM, Chaisson RE, Moore RD
  Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med. 1999 Jul 20;131(2):81-7.
•   Malow RM, Baker SM, Klimas N, Antoni MH, Schneiderman N, Penedo FJ, Ziskind D, Page B, McMahon R
  Adherence to complex combination antiretroviral therapies by HIV-positive drug abusers. Psychiatr Serv. 1998 Aug;49(8):1021-2, 1024. Erratum in: Psychiatr Serv 1998 Nov;49(11):1487. McPherson S [corrected to Baker SM].
•   Malta M, Magnanini MM, Strathdee SA, Bastos FI
  Adherence to antiretroviral therapy among HIV-infected drug users: a meta-analysis. AIDS Behav. 2010 Aug;14(4):731-47. doi: 10.1007/s10461-008-9489-7. Epub 2008 Nov 20.
•   Milam J, Richardson JL, McCutchan A, Stoyanoff S, Weiss J, Kemper C, Larsen RA, Hollander H, Weismuller P, Bolan R
  Effect of a brief antiretroviral adherence intervention delivered by HIV care providers. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):356-63.
•   Møller T, Linaker OM
  Using brief self-reports and clinician scales to screen for substance use disorders in psychotic patients. Nord J Psychiatry. 2010 Apr;64(2):130-5. doi: 10.3109/08039480903274423.
•   Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G
  Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007 Apr 17;146(8):564-73.
•   Parsons JT, Golub SA, Rosof E, Holder C
  Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):443-50.
•   Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N
  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000 Jul 4;133(1):21-30. Erratum in: Ann Intern Med 2002 Feb 5;136(3):253.
•   Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR
  Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis. 2007 Oct 1;45(7):908-15. Epub 2007 Aug 20.
•   Platt L, Bobrova N, Rhodes T, Uusküla A, Parry JV, Rüütel K, Talu A, Abel K, Rajaleid K, Judd A
  High HIV prevalence among injecting drug users in Estonia: implications for understanding the risk environment. AIDS. 2006 Oct 24;20(16):2120-3.
•   Radloff L
  The CES-D scale: a self-report depression scale for research in the general population. Appl Psych Meas. 1977;1:385-401
•   Reynolds NR, Neidig JL
  Characteristics of nausea reported by HIV-infected patients initiating combination antiretroviral regimens. Clin Nurs Res. 2002 Feb;11(1):71-88.
•   Rüütel K, Pisarev H, Loit HM, Uusküla A
  Factors influencing quality of life of people living with HIV in Estonia: a cross-sectional survey. J Int AIDS Soc. 2009 Jul 16;12:13. doi: 10.1186/1758-2652-12-13.
•   Rüütel K, Uusküla A, Minossenko A, Loit HM
  Quality of life of people living with HIV and AIDS in Estonia. Cent Eur J Public Health. 2008 Sep;16(3):111-5.
•   Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M
  Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. Addiction. 1993 Jun;88(6):791-804.
•   Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, Athey LA, Keesey JW, Goldman DP, Berry SH, Bozzette SA
  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999 Jun 23-30;281(24):2305-15.
•   Sherer R
  Adherence and antiretroviral therapy in injection drug users. JAMA. 1998 Aug 12;280(6):567-8.
•   Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N
  Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006 Dec 1;43 Suppl 1:S23-35.
•   Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulsky JP, Barnett P, Hall S
  Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend. 2007 Apr 17;88(1):54-63. Epub 2006 Oct 23.
•   Stone VE
  Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 2001 Sep 15;33(6):865-72. Epub 2001 Aug 13. Review.
•   Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, Schechter MT, Hogg RS
  Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998 Aug 12;280(6):547-9.
•   Talu A, Rajaleid K, Abel-Ollo K, Rüütel K, Rahu M, Rhodes T, Platt L, Bobrova N, Uusküla A
  HIV infection and risk behaviour of primary fentanyl and amphetamine injectors in Tallinn, Estonia: implications for intervention. Int J Drug Policy. 2010 Jan;21(1):56-63. doi: 10.1016/j.drugpo.2009.02.007. Epub 2009 Apr 22.
•   Torres-Madriz G, Lerner D, Ruthazer R, Rogers WH, Wilson IB
  Work-related barriers and facilitators to antiretroviral therapy adherence in persons living with HIV infection. AIDS Behav. 2011 Oct;15(7):1475-82. doi: 10.1007/s10461-010-9667-2.
•   Uusküla A, Kalikova A, Zilmer K, Tammai L, DeHovitz J
  The role of injection drug use in the emergence of Human Immunodeficiency Virus infection in Estonia. Int J Infect Dis. 2002 Mar;6(1):23-7.
•   Uusküla A, Kals M, Rajaleid K, Abel K, Talu A, Rüütel K, Platt L, Rhodes T, Dehovitz J, Des Jarlais D
  High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. J Public Health (Oxf). 2008 Jun;30(2):119-25. doi: 10.1093/pubmed/fdn014. Epub 2008 Feb 28.
•   WHO/UNAIDS/UNICEF
  Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report, April 2007. http://www.who.int/hiv/mediacentre/universal_access_progress_report_en.pdf
•   Wolfe D
  Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy. 2007 Aug;18(4):246-54. Epub 2007 Mar 23.

HAART Adherence Among HIV-infected Persons and the Factors Affecting Treatment Adherence

Details for clinical trial NCT01369056